Handelen Kura Oncology Inc - KURA CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.08 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Kura Oncology Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 13.84 |
| Open* | 13.64 |
| 1-Jaarlijkse Verandering* | 14.24% |
| Dagelijks bereik* | 13.17 - 13.85 |
| 52 wekelijks bereik | 9.49-19.93 |
| Weekgemiddelde volume (10 dagen) | 782.19K |
| Gemiddeld volume (3 maanden) | 13.01M |
| Marktkapitalisatie | 913.66M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 68.44M |
| Omzet | N/A |
| EPS | -2.04 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.88 |
| Volgende inkomsten datum | Aug 1, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 13.32 | -0.09 | -0.67% | 13.41 | 13.94 | 13.16 |
| May 25, 2023 | 13.84 | 0.12 | 0.87% | 13.72 | 13.99 | 13.24 |
| May 24, 2023 | 13.94 | 0.35 | 2.58% | 13.59 | 14.24 | 13.48 |
| May 23, 2023 | 13.90 | 0.68 | 5.14% | 13.22 | 14.28 | 13.22 |
| May 22, 2023 | 13.36 | 0.51 | 3.97% | 12.85 | 13.53 | 12.74 |
| May 19, 2023 | 12.81 | 0.49 | 3.98% | 12.32 | 13.01 | 12.04 |
| May 18, 2023 | 12.27 | 0.13 | 1.07% | 12.14 | 12.54 | 11.93 |
| May 17, 2023 | 12.39 | -0.58 | -4.47% | 12.97 | 12.97 | 12.11 |
| May 16, 2023 | 12.49 | 0.24 | 1.96% | 12.25 | 12.49 | 11.60 |
| May 15, 2023 | 12.63 | 0.54 | 4.47% | 12.09 | 12.91 | 12.07 |
| May 12, 2023 | 12.22 | 0.16 | 1.33% | 12.06 | 12.38 | 11.87 |
| May 11, 2023 | 12.33 | 1.33 | 12.09% | 11.00 | 12.50 | 11.00 |
| May 10, 2023 | 11.40 | 0.35 | 3.17% | 11.05 | 11.55 | 11.03 |
| May 9, 2023 | 11.35 | 0.37 | 3.37% | 10.98 | 11.58 | 10.96 |
| May 8, 2023 | 11.16 | 0.18 | 1.64% | 10.98 | 11.29 | 10.98 |
| May 5, 2023 | 11.34 | 0.13 | 1.16% | 11.21 | 11.49 | 11.13 |
| May 4, 2023 | 11.17 | 0.91 | 8.87% | 10.26 | 11.34 | 10.26 |
| May 3, 2023 | 10.64 | 0.57 | 5.66% | 10.07 | 10.74 | 10.02 |
| May 2, 2023 | 10.17 | -0.18 | -1.74% | 10.35 | 10.53 | 9.95 |
| May 1, 2023 | 10.40 | 0.73 | 7.55% | 9.67 | 10.51 | 9.50 |
Kura Oncology Inc Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Tuesday, May 30, 2023 | ||
| Tijd (UTC) (UTC) 17:30 | Land US
| Evenement Kura Oncology Inc at TD Cowen Oncology Innovation Summit (Virtual) Kura Oncology Inc at TD Cowen Oncology Innovation Summit (Virtual)Forecast -Previous - |
| Wednesday, May 31, 2023 | ||
| Tijd (UTC) (UTC) 15:30 | Land US
| Evenement Kura Oncology Inc Annual Shareholders Meeting Kura Oncology Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, June 7, 2023 | ||
| Tijd (UTC) (UTC) 19:00 | Land US
| Evenement Kura Oncology Inc at Jefferies Healthcare Conference Kura Oncology Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Tuesday, August 1, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Kura Oncology Inc Earnings Release Q2 2023 Kura Oncology Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q3 2023 Kura Oncology Inc Earnings Release Q3 2023 Kura Oncology Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 139.865 | 131.458 | 91.899 | 67.479 | 63.381 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 47.053 | 46.537 | 31.502 | 19.653 | 16.096 |
| Onderzoek & Ontwikkeling | 92.812 | 84.721 | 60.397 | 47.826 | 46.787 |
| Bedrijfsresultaat | -139.865 | -131.458 | -91.899 | -67.479 | -63.381 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 3.925 | 0.992 | 2.223 | 4.094 | 2.199 |
| Overige, Netto | 0.1 | 0.051 | 0.245 | 0.735 | |
| Netto inkomen voor belastingen | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Netto inkomen na belastingen | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Netto inkomen voor extra. Posten | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Netto inkomen | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Verwaterd Netto Inkomen | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Verwaterd Gewogen Gemiddelde Aandelen | 66.99 | 66.352 | 53.077 | 41.946 | 35.191 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.02777 | -1.96627 | -1.68858 | -1.50527 | -1.71768 |
| Verwaterde Genormaliseerde Winst per Aandeel | -2.02777 | -1.96326 | -1.68858 | -1.50527 | -1.70353 |
| Ongebruikelijke uitgaven (inkomsten) | 0.2 | 0.498 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 36.566 | 35.156 | 36.594 | 35.333 | 32.782 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 11.374 | 12.488 | 11.621 | 11.075 | 11.869 |
| Onderzoek & Ontwikkeling | 25.192 | 22.668 | 24.973 | 24.258 | 20.913 |
| Bedrijfsresultaat | -36.566 | -35.156 | -36.594 | -35.333 | -32.782 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 2.497 | 2.042 | 1.09 | 0.564 | 0.329 |
| Overige, Netto | |||||
| Netto inkomen voor belastingen | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Netto inkomen na belastingen | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Netto inkomen voor extra. Posten | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Netto inkomen | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Verwaterd Netto Inkomen | -34.069 | -33.114 | -35.504 | -34.769 | -32.453 |
| Verwaterd Gewogen Gemiddelde Aandelen | 68.403 | 67.791 | 66.889 | 66.672 | 66.607 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.49806 | -0.48847 | -0.53079 | -0.52149 | -0.48723 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.49806 | -0.48847 | -0.53079 | -0.52149 | -0.48723 |
| Ongebruikelijke uitgaven (inkomsten) |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 446.426 | 522.289 | 637.292 | 239.603 | 181.197 |
| Geldmiddelen en kortetermijnbeleggingen | 437.985 | 517.96 | 633.32 | 236.891 | 178.985 |
| Geldmiddelen & Equivalenten | 51.802 | 90.672 | 325.493 | 26.135 | 16.119 |
| Korte Termijn Investeringen | 386.183 | 427.288 | 307.827 | 210.756 | 162.866 |
| Totale Vorderingen, Netto | 0.03 | 0.224 | |||
| Prepaid Expenses | 8.441 | 4.329 | 3.972 | 2.682 | 1.988 |
| Total Assets | 456.306 | 534.051 | 647.212 | 241.972 | 182.379 |
| Property/Plant/Equipment, Total - Net | 6.382 | 8.246 | 8.355 | 0.278 | 0 |
| Property/Plant/Equipment, Total - Gross | 7.985 | 9.09 | 8.641 | 0.136 | 0.092 |
| Accumulated Depreciation, Total | -1.603 | -0.844 | -0.286 | -0.092 | -0.092 |
| Other Long Term Assets, Total | 3.498 | 3.516 | 1.565 | 2.091 | 1.182 |
| Total Current Liabilities | 24.057 | 22.455 | 26.024 | 15.564 | 13.615 |
| Accounts Payable | 1.533 | 3.236 | 2.753 | 3.526 | 3.89 |
| Payable/Accrued | 0.23 | ||||
| Accrued Expenses | 22.524 | 19.219 | 20.271 | 11.788 | 9.495 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 36.028 | 27.442 | 36.307 | 23.191 | 21.394 |
| Total Long Term Debt | 9.158 | 0 | 4.25 | 7.25 | 7.5 |
| Long Term Debt | 9.158 | 0 | 4.25 | 7.25 | 7.5 |
| Other Liabilities, Total | 2.813 | 4.987 | 6.033 | 0.377 | 0.279 |
| Total Equity | 420.278 | 506.609 | 610.905 | 218.781 | 160.985 |
| Preferred Stock - Non Redeemable, Net | 0 | ||||
| Common Stock | 0.007 | 0.007 | 0.007 | 0.005 | 0.004 |
| Additional Paid-In Capital | 997.111 | 941.359 | 913.354 | 431.322 | 310.849 |
| Retained Earnings (Accumulated Deficit) | -568.808 | -432.968 | -302.502 | -212.877 | -149.737 |
| Other Equity, Total | -8.032 | -1.789 | 0.046 | 0.331 | -0.131 |
| Total Liabilities & Shareholders’ Equity | 456.306 | 534.051 | 647.212 | 241.972 | 182.379 |
| Total Common Shares Outstanding | 68.314 | 66.572 | 66.194 | 45.384 | 38.148 |
| Current Port. of LT Debt/Capital Leases | 0 | 3 | 0.25 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 416.45 | 446.426 | 436.391 | 459.786 | 487.034 |
| Geldmiddelen en kortetermijnbeleggingen | 405.9 | 437.985 | 427.775 | 450.258 | 480.075 |
| Geldmiddelen & Equivalenten | 27.059 | 51.802 | 90.937 | 39.257 | 33.832 |
| Korte Termijn Investeringen | 378.841 | 386.183 | 336.838 | 411.001 | 446.243 |
| Prepaid Expenses | 10.55 | 8.441 | 8.616 | 9.528 | 6.959 |
| Total Assets | 425.975 | 456.306 | 447.988 | 471.425 | 498.585 |
| Property/Plant/Equipment, Total - Net | 5.761 | 6.382 | 7.018 | 7.265 | 7.716 |
| Property/Plant/Equipment, Total - Gross | 7.57 | 7.985 | 8.415 | 8.469 | 8.737 |
| Accumulated Depreciation, Total | -1.809 | -1.603 | -1.397 | -1.204 | -1.021 |
| Other Long Term Assets, Total | 3.764 | 3.498 | 4.579 | 4.374 | 3.835 |
| Total Current Liabilities | 19.233 | 24.057 | 24.745 | 17.873 | 17.725 |
| Accounts Payable | 3.291 | 1.533 | 1.746 | 1.337 | |
| Accrued Expenses | 15.942 | 22.524 | 22.999 | 16.478 | 16.388 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Total Liabilities | 30.792 | 36.028 | 28.367 | 21.934 | 22.335 |
| Total Long Term Debt | 9.2 | 9.158 | 0 | 0 | 0 |
| Long Term Debt | 9.2 | 9.158 | |||
| Other Liabilities, Total | 2.359 | 2.813 | 3.622 | 4.061 | 4.61 |
| Total Equity | 395.183 | 420.278 | 419.621 | 449.491 | 476.25 |
| Common Stock | 0.007 | 0.007 | 0.007 | 0.007 | 0.007 |
| Additional Paid-In Capital | 1003.95 | 997.111 | 964.724 | 957.489 | 948.312 |
| Retained Earnings (Accumulated Deficit) | -602.877 | -568.808 | -535.694 | -500.19 | -465.421 |
| Other Equity, Total | -5.896 | -8.032 | -9.416 | -7.815 | -6.648 |
| Total Liabilities & Shareholders’ Equity | 425.975 | 456.306 | 447.988 | 471.425 | 498.585 |
| Total Common Shares Outstanding | 68.439 | 68.314 | 66.894 | 66.838 | 66.636 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Payable/Accrued | 1.395 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -135.84 | -130.466 | -89.625 | -63.14 | -60.447 |
| Geldmiddelen uit Operationele Activiteiten | -110.062 | -104.551 | -69.83 | -54.76 | -48.655 |
| Geldmiddelen uit Operationele Activiteiten | 0.759 | 0.558 | 0.194 | 0 | 0.01 |
| Niet-Geldelijke Posten | 28.001 | 28.581 | 13.217 | 8.306 | 7.401 |
| Contant Betaalde Rente | 0.073 | 0.784 | 0.419 | 0.43 | 0.641 |
| Veranderingen in het Operationeel Kapitaal | -2.982 | -3.224 | 6.384 | 0.074 | 4.381 |
| Geldmiddelen uit Investeringsactiviteiten | 32.627 | -126.835 | -99.936 | -46.325 | -79.3 |
| Overige Cash Flow investeringsposten, Totaal | 33.253 | -125.688 | -97.765 | -46.325 | -79.3 |
| Geldmiddelen uit Financieringsactiviteiten | 38.565 | -3.435 | 469.334 | 111.101 | 132.641 |
| Uitgifte (Aflossing) van aandelen, netto | 29.14 | 4.426 | 469.584 | 111.101 | 133.264 |
| Uitgifte (Aflossing) van Schulden, Netto | 10 | -7.25 | -0.25 | 0 | -0.623 |
| Nettowijziging in Geldmiddelen | -38.87 | -234.821 | 299.568 | 10.016 | 4.686 |
| Kapitaaluitgaven | -0.626 | -1.147 | -2.171 | ||
| Financiering van Cash Flow Posten | -0.575 | -0.611 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -34.069 | -135.84 | -102.726 | -67.222 | -32.453 |
| Cash From Operating Activities | -35.872 | -110.062 | -83.532 | -62.522 | -32.181 |
| Cash From Operating Activities | 0.206 | 0.759 | 0.553 | 0.36 | 0.177 |
| Non-Cash Items | 5.266 | 28.001 | 21.777 | 15.052 | 7.75 |
| Changes in Working Capital | -7.275 | -2.982 | -3.136 | -10.712 | -7.655 |
| Cash From Investing Activities | 11.129 | 32.627 | 79.945 | 8.135 | -24.962 |
| Capital Expenditures | -0.036 | -0.626 | -0.614 | -0.233 | -0.049 |
| Other Investing Cash Flow Items, Total | 11.165 | 33.253 | 80.559 | 8.368 | -24.913 |
| Cash From Financing Activities | 0 | 38.565 | 3.852 | 2.972 | 0.303 |
| Issuance (Retirement) of Stock, Net | 0 | 29.14 | 3.852 | 2.972 | 0.303 |
| Issuance (Retirement) of Debt, Net | 10 | 0 | 0 | 0 | |
| Net Change in Cash | -24.743 | -38.87 | 0.265 | -51.415 | -56.84 |
| Financing Cash Flow Items | -0.575 | 0 | 0 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 9.8351 | 6730983 | 2930000 | 2023-03-31 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 9.6998 | 6638371 | 0 | 2023-03-31 | LOW |
| Suvretta Capital Management, LLC | Hedge Fund | 9.6047 | 6573335 | 196520 | 2023-03-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.7018 | 4586588 | 24914 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.6148 | 3842678 | -603749 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.0748 | 3473109 | 78051 | 2023-03-31 | LOW |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 4.5369 | 3105000 | 0 | 2023-03-31 | |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 3.5799 | 2450031 | -218533 | 2023-03-31 | MED |
| Holocene Advisors, LP | Hedge Fund | 3.5615 | 2437463 | -101142 | 2023-03-31 | HIGH |
| Deerfield Management Company, L.P. | Hedge Fund | 3.482 | 2383000 | 0 | 2023-03-31 | MED |
| Citadel Advisors LLC | Hedge Fund | 2.8282 | 1935607 | 1211847 | 2023-03-31 | HIGH |
| Foresite Capital Management, LLC | Private Equity | 2.7031 | 1849947 | 0 | 2023-03-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.6814 | 1835084 | 133912 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 2.5104 | 1718056 | 18056 | 2023-03-31 | LOW |
| TCG Crossover Management, LLC | Investment Advisor | 2.0802 | 1423642 | 0 | 2023-03-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8798 | 1286540 | 57110 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 1.806 | 1236000 | 164000 | 2023-03-31 | HIGH |
| Commodore Capital LP | Hedge Fund | 1.7606 | 1204958 | 105551 | 2023-03-31 | MED |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 1.7211 | 1177921 | 126162 | 2023-03-31 | LOW |
| Wilson (Troy Edward) | Individual Investor | 1.7016 | 1164537 | -484555 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group530K+
Handelaren
87K+
Actieve klanten per maand
$46M+
Maandelijks beleggingsvolume
$31M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Kura Oncology Inc Company profile
Over Kura Oncology Inc
Kura Oncology, Inc. is een biofarmaceutisch bedrijf in een klinische fase. Het segment van de onderneming houdt zich bezig met de ontdekking en ontwikkeling van geneesmiddelen voor de behandeling van kanker. De pijplijn bestaat uit kleine molecule productkandidaten die zich richten op kanker signaalwegen. Het ontwikkelt zijn voornaamste kandidaat-product, tipifarnib, een farnesyltransferaseremmer, voor zowel solide tumoren als hematologische indicaties. Het ontwikkelt KO-539, een kleine molecule-remmer van de Lysine K-specifieke methyltransferase 2A (KMT2A) interactie, voor de behandeling van genetisch bepaalde subsets van acute leukemieën, waaronder acute myeloïde leukemie (AML) en acute lymfoblastische leukemie (ALL).
| Industry: | Bio Therapeutic Drugs |
12730 High Bluff Drive, Suite 400
SAN DIEGO
CALIFORNIA 92130
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 530.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen